Has Acotiamide been declared for production in 2025?

Acotiamide (Acotiamide) is an innovative gastric motility drug for functional dyspepsia (Functional Dyspepsia, FD). Its mechanism of action mainly relieves upper abdominal discomfort, early satiety, gastric bloating and other symptoms by enhancing gastric emptying and improving gastrointestinal motility. Since its official launch in Japan in 2013, acotiamide has gained widespread attention in the Asian market due to its unique gastric motility regulation effect. It is mainly used clinically for patients with functional dyspepsia, especially for indigestion symptoms caused by delayed gastric emptying or abnormal gastrointestinal motility. The common oral dosage is 100mg*100 tablets, which is convenient for long-term use and dosage management.

As of 2025Japan and Russia are still the main markets for the global production and marketing of acotiamide. The Japanese version of drugs are produced by the original manufacturers in strict accordance with drug registration specifications, and the quality and efficacy of the drugs have been clinically verified for a long time. The Russian version has also received registration approval locally to meet the clinical needs of patients with functional dyspepsia. Although the marketing process of acotiamide is relatively slow in other countries and regions, some regions have started production application or clinical registration evaluation.

In Whether there will be new production applications for acotiamide in 2025 mainly depends on the approval pace of various countries' drug regulatory agencies and the market layout of the company. According to the overseas drug registration database, the Japanese version and the Russian version are still the main marketing channels. Some pharmaceutical companies have launched clinical registration plans in other countries in the Asia-Pacific region, but large-scale marketing has not yet occurred. In the next few years, as awareness of functional dyspepsia increases and the demand for gastric motility drugs grows, the production application for acotiamide is expected to be approved in more countries.

As an innovative gastric motility drug, acotiamide has good safety in clinical use, and long-term observation shows that the drug is highly tolerable. The advancement of production application not only involves drug approval, but also includes quality control, drug stability verification and clinical data submission, which are all important links to ensure the safety and effectiveness of drugs.

Reference: https://www.rad-ar.or.jp/siori/english/search/result?n=33322